Development of solid nanoparticles based on hydroxypropyl-β- cyclodextrin aimed for the colonic transmucosal delivery of diclofenac sodium

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 4, 2011, Pages 472-482

  Gavini, Elisabetta ^a   Spada, Gianpiera ^a   Rassu, Giovanna ^a   Cerri, Guido ^a   Brundu, Antonio ^a   Cossu, Massimo ^a   Sorrenti, Milena ^b   Giunchedi, Paolo ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Colon delivery; Eudragit L 100; Hydroxypropyl cyclodextrin; Solid nanoparticles; Transmucosal administration

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DICLOFENAC; SOLID LIPID NANOPARTICLE;

ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOEMULSION; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; PROCESS DEVELOPMENT; SOLID STATE; SWINE; X RAY POWDER DIFFRACTION;

ADMINISTRATION, MUCOSAL; ANIMALS; BETA-CYCLODEXTRINS; CACO-2 CELLS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; COLON; CRYSTALLIZATION; DICLOFENAC; DRUG CARRIERS; EMULSIONS; HUMANS; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYMETHACRYLIC ACIDS; SWINE;

EID: 79952716405     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01220.x     Document Type: Article

References (52)

1. Loftsson T, Olasson JH. Cyclodextrins: new drug delivery systems. Int J Dermatol 1998; 37: 241-246. (Pubitemid 28189682)
2. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001; 225: 15-30. (Pubitemid 32728196)
3. Uekama K et al. Recent aspects of cyclodextrin-based drug delivery system. J Incl Phenom Macrocycl Chem 2006; 56: 3-8.
4. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Del Rev 2007; 59: 645-666. (Pubitemid 47299263)
5. Haeberlin B et al. Cyclodextrins, useful excipients for oral peptide administration. Int J Pharm 1996; 137: 103-110. (Pubitemid 26238517)
6. Lahiani-Skiba M et al. Interaction between hydrophilic drug and α-cyclodextrins:physico-chemical aspects. J Incl Phenom Macrocycl Chem 2007; 57: 211-217.
7. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329: 1-11. (Pubitemid 44937538)
8. Challa R et al. Cyclodextrins in drug delivery: an updated review. AAPS Pharm Sci Tech 2005; 6: 329-357.
9. Hedges AR. Industrial applications of cyclodextrins. Chem Rev 1998; 98: 2035-2044. (Pubitemid 128633446)
10. Singh M et al. Biotechnological applications of cyclodextrins. Biotechnol Adv 2002; 20: 341-359. (Pubitemid 35348280)
11. Sigurosson HH et al. Effects of cyclodextrins on hydrocortisone permeability through semi-permeable membranes. J Incl Phenom Macroc Chem 2002; 44: 163-167.
12. Loftsson T et al. Cyclodextrins and drug permeability through semi-permeable cellophane membranes. Int J Pharm 2002; 232: 35-43. (Pubitemid 34076752)
13. Figueiras A et al. In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm 2009; 71: 339-345.
14. Klein S et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-b-cyclodextrin. J Pharm Pharmacol 2009; 61: 23-30.
15. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci 2003; 6: 33-66. (Pubitemid 37207241)
16. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 8: 360.
17. MacFarlane GT, Cummings JH. The colonic flora, fermentation, and large bowel digestive function. In: Phillips SF et al, ed. The Large Intestine, Physiology, Pathophysiology, and Disease. New York: Raven Press, 1991: 51.
18. des Rieux A et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116: 1-27.
19. Cheng G et al. Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium. World J Gastroenterol 2004; 10: 1769-1774. (Pubitemid 38931202)
20. Ali Asghar LF, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharmaceut Sci 2006; 9: 327-338. (Pubitemid 46614339)
21. Jain A et al. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharmaceut Sci 2007; 10: 86-128. (Pubitemid 46692379)
22. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Del Rev 2004; 57: 247-265.
23. Yang L et al. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235: 1-15. (Pubitemid 34185432)
24. Ashford M, Fell JT. Targeting drugs to the colon: delivery systems for oral administration. J Drug Target 1994; 2: 241-258.
25. Freire C et al. Starch-based coatings for colon-specific delivery. Part II: physico-chemical properties and in vitro drug release from high amylose maize starch films. Eur J Pharm Biopharm 2009; 72: 587-594.
26. Florence AT et al. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995; 36: 39-46.
27. Passerini N et al. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J Pharm Pharmacol 2009; 61: 559-567.
28. Puglia C et al. Evaluation of percutaneous absorption of the repellent diethyltoluamide and the sunscreen ethylhexyl p-methoxycinnamate-loaded solid lipid nanoparticles: an in-vitro study. J Pharm Pharmacol 2009; 61: 1013-1019.
29. Weiss-Angeli V et al. Development of an original method to study drug release from polymeric nanocapsules in the skin. J Pharm Pharmacol 2010; 62: 35-45.
30. Pinto-Reis C et al. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2: 53-65.
31. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23: 1417-1450. (Pubitemid 43993807)
32. Dûchene D et al. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Del Rev 1999; 36: 29-40.
33. Francis MF et al. Polymeric micelles for oral drug delivery: why and how. Pure Appl Chem 2004; 76: 1321-1335.
34. Eerikäinen H, Kauppinen EI. Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int J Pharm 2003; 263: 69-83. (Pubitemid 37087934)
35. Quinteros DA et al. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Eur J Pharm Sci 2008; 33: 72-79. (Pubitemid 350235193)
36. Shivakumar HN et al. Design and optimization of diclofenac sodium controlled release solid dispersions by response surface methodology. Indian J Pharm Sci 2008; 70: 22-30.
37. Zheng Y et al. Lack of effect of cyclodextrin and its water-soluble derivatives on in vitro drug transport across rat intestinal epithelium. Int J Pharm 2006; 309: 123-128. (Pubitemid 43129474)
38. Prego C et al. Transmucosal macromolecular drug delivery. J Control Release 2005; 101: 151-162. (Pubitemid 39600979)
39. Sandri G et al. Nanoparticles based on N-Trimethylchitosan: evaluation of absorption properties using in vitro (Caco2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm 2007; 65: 68-77. (Pubitemid 44827693)
40. United States Pharmacopeia Edition 24, 2000: 1947.
41. Cossu M et al. A New Diffusion System for the Evaluation of Transmucosal Permeation across Synthetic or Biological Membranes. Naples, Italy: Conference: Innovation in Drug Delivery from Biomaterials to Devices, 2007: 343.
42. Moddaresi M et al. Tocopheryl acetate disposition in porcine and human skin when administered using lipid nanocarriers. J Pharm Pharmacol 2010; 62: Special Issue 762-769.
43. El-Sayed YM et al. A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. J Pharm Pharmacol 1988; 40: 727-729.
44. Miro A et al. Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: role of cyclodextrins and implications in oral drug delivery. Eur J Pharm Biopharm 2009; 72: 76-82.
45. Almgren M. Mixed micelles and other structures in the solubilization of bilayer lipid membranes by surfactants. Biochim Biophys Acta (BBA) - Biomembranes 2000; 1508: 146-163.
46. Jones MN. Invited review. Surfactants in membrane solubilisation. Int J Pharm 1999; 177: 137-159. (Pubitemid 29073411)
47. Simoes SI et al. Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween80. Eur J Pharm Sci 2005; 26: 307-317. (Pubitemid 41282799)
48. Muller RH et al. DissoCubes - a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone MJ et al, eds. Modified-Release Drug Delivery Technology. New York, NY: Marcel Dekker, 2003: 135-149.
49. Gould S, Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 2005; 43: 1451-1459.
50. Lewinski N et al. Cytotoxicity of nanoparticles. Small 2008; 4: 26-49.
51. Medina C et al. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150: 552-558. (Pubitemid 46355555)
52. Kroll A et al. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm 2009; 72: 370-377.